Abnormal LH pulsatility in women with hyperprolactinaemic amenorrhoea normalizes after bromocriptine treatment: Deconvolution-based assessment

A. Sartorio, A. Pizzocaro, D. Liberati, G. De Nicolao, J. D. Veldhuis, G. Faglia

Research output: Contribution to journalArticle


OBJECTIVE: The present study examines the LH secretory process in hyperprolactinaemic women before, during and after bromocriptine therapy, using restrictive clinical selection criteria as well as improved methodological tools. PATIENTS AND DESIGN: Six women (aged 20-40 years) with microprolactinomas (mean ± SE prolactin, PRL: 2478 ± 427 mU/l, range: 1370- 3800 mU/l) and four age- and sex-matched healthy controls were admitted to the study. After an overnight fast, all patients and controls had blood samples withdrawn at 10 minute intervals for 6 h (during saline infusion) from 0800 h to 1400 h to determine serum LH and PRL concentrations. After baseline evaluation, patients were treated with bromocriptine, which was started at a daily dose of 1-25 mg for 7 days; the dose was then increased to 2-5 mg daily for the next 7 days and subsequently to 2.5 mg twice daily. PRL levels were evaluated at weekly intervals after the beginning of bromocriptine therapy for the duration of the study. The 6 h pulsatility study was repeated on four patients during treatment at a time when PRL levels were decreased, although not normalized (PRL range: 450-1350 mU/l) and, on four patients; with the attainment of normal serum PRL levels (PRL

Original languageEnglish
Pages (from-to)703-712
Number of pages10
JournalClinical Endocrinology
Issue number6
Publication statusPublished - 2000


ASJC Scopus subject areas

  • Endocrinology

Cite this